Lenalidomide Genthon

Lenalidomide, the active ingredient in Lenalidomide Genthon, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is employed in the treatment of certain blood cancers, notably multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenalidomide Genthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Lenalidomide is used in hematologic malignancies that respond to immunomodulatory therapy. - Multiple myeloma: improves progression‑free survival and overall response rates in relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission. - Mantle cell lymphoma (in combination with rituximab): enhances overall response when added to standard chemo‑immunotherapy.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to easy bruising. - Diarrhea: loose stools of mild to moderate intensity. - Constipation: difficulty passing stool. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia: profound drop in neutrophils requiring medical intervention. - Severe thrombocytopenia: platelet counts <20 × 10⁹/L with bleeding risk. - Secondary primary malignancies: emergence of new cancers. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome.

When prescribing Lenalidomide, clinicians should observe several safety precautions to minimize risk. - Monitor blood counts: perform complete blood count regularly to detect cytopenias. - Assess thrombotic risk: evaluate history of clotting disorders before initiating therapy. - Avoid pregnancy: contraindicated in pregnancy; ensure effective contraception for both sexes. - Use contraception: employ two reliable methods throughout treatment and for at least four weeks after discontinuation. - Adjust for renal impairment: dose may need modification in patients with reduced kidney function. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Lenalidomide interacts with several drug classes; awareness of these interactions guides safe co‑administration.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole): can markedly increase lenalidomide exposure. - Potent CYP3A4 inducers (e.g., rifampin): may substantially lower drug levels and reduce efficacy. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): monitor INR closely as bleeding risk may rise. - Antiplatelet agents (aspirin, clopidogrel): watch for additive bleeding tendencies. - Other immunomodulatory agents (e.g., pomalidomide): increased potential for myelosuppression. - CYP3A4 substrates with narrow therapeutic index: consider dose adjustments or therapeutic drug monitoring.